Glycogenosis type II (acid maltase deficiency) by Reuser, A.J.J. (Arnold) et al.
Glycogen storage disease type II (GSD IVglycogenosis type II/Pompe’s 
disease/acid maltase deficiency) is caused by the deficiency of lyso- 
soma1 a-glucosidase resulting in lysosomal accumulation of glycogen. 
The disease is inherited as an autosomal recessive trait and is clinically 
heterogeneous. Early and late onset phenotypes are distinguished. In- 
sight in the molecular nature of the lysosomal a-glucosidase deficiency 
and the underlying genetic defect has increased significantly during 
the past decade. This minireview on GSD II was written at the occasion 
of The International Symposium on Glycolytic and Mitochondria1 De- 
fects in Muscle and Nerve, held in Osaka, Japan, July 1994. It is an 
update of current literature, but also includes original data from the 
collaborating authors on mutations occurring in the lysosornal a-glu- 
cosidase gene and on prenatal diagnosis by chorionic villus sampling. 
The genotype-phenotype correlation and the prospects for therapy are 
addressed. 0 1995 John Wiley & Sons, Inc. 
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Glycogenosis type 11 (GSD 11) is one of the more 
than ten glycogen storage diseases recognized at 
present as separate genetic entities.28 Characteris- 
tic for this disease is the organelle bound, lysosom- 
al, accumulation of glycogen as opposed to the cy- 
toplasmic accumulation of glycogen in the other 
glycogenoses. The disease was described first in 
1932 by the Dutch pathologist, J.C. Pompe, from 
whom it lends its name Pompe’s disease.34 The 
name “acid maltase deficiency” was introduced in 
1963 after identification of the missing enzyme.14 
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That publication by H.G. Hers on the primary de- 
fect in Pompe’s disease has accelerated the subse- 
quent discovery of lysosomal enzyme deficiencies 
in more than 30 other lysosomal storage diseases. 
In addition, deficiencies of nonenzymic lysosomal 
proteins were discovered. 
Since the discovery of the primary lysosomal 
a-glucosidase deficiency in GSD I1 important new 
information has been acquired on the structure 
and function of the enzyme, and progress has been 
made with elucidating the underlying genetic de- 
fect in case of a-glucosidase deficiency. Enzyme 
therapy is under development. 
This minireview starts with a brief description 
of the clinical phenotypes of GSD I1 and a review 
of recent findings pertaining to the structure and 
function of lysosomal a-glucosidase. The  geno- 
type-phenotype correlation is addressed with ref- 
erence to the mutations discovered so far and the 
residual a-glucosidase activity in cultured fibro- 
blasts from a large series of patients. Original data 
on the prenatal diagnosis by chorionic villus sam- 
pling in 42 pregnancies at risk are presented, and 
the prospects for enzyme therapy are discussed. 
THE CLINICAL PHENOTYPE 
Among patients with GSD I1 a pronounced varia- 
tion is observed with regard to age of onset and 
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clinical presentation. This has led to the distinction 
of three subtypes of the disease, an infantile, juve- 
nile, and adult In patients with the in- 
fantile form of GSD I1 symptoms become apparent 
within the first 3 months of life. Mostly, poor mo- 
tor development and failure to thrive are noticed 
first. On clinical examination there is generalized 
hypotonia with muscle wasting, increased respi- 
ration rate with sternal retractions, moderate 
enlargement of the liver, and protrusion of the 
tongue. Ultrasound examination of the heart 
shows a progressive hypertrophic cardiomyopathy , 
eventually leading to insufficient cardiac output. 
The ECG is characterized by marked left axis de- 
viation, a short PR interval, large QRS complexes, 
inverted T waves, and ST depressions. The disease 
shows a rapidly progressive course leading to car- 
diorespiratory failure within the first year of life. 
On histological examination at autopsy lysosomal 
glycogen storage is observed in various tissues, 
most pronounced in heart and skeletal muscle. 
Patients with the adult form of GSD I1 may not 
experience symptoms within the first two decades 
of life. In this clinical subtype only skeletal muscles 
are involved with predilection of those of the limb 
girdle, the trunk and the diaphragm. Difficulty in 
climbing stairs is often the initial complaint. The 
respiratory impairment varies considerably. It can 
dominate the clinical picture, or it is not experi- 
enced by the patient until late in life.7 The eldest 
patient recorded at the University Hospital Rotter- 
dam was referred at the age of 53, and died at the 
age of 72 because of respiratory insufficiency, 
which is the main cause of death in late onset 
GSD 11. 
Besides infantile and adult variants an interme- 
diate juvenile subtype is distinguished. In these pa- 
tients symptoms usually become apparent in the 
first decade of life. As in adult GSD 11, skeletal 
muscle weakness is the major problem, cardiac in- 
volvement does not occur. In many cases nightly 
ventilatory support is ultimately needed. Pulmo- 
nary infections in combination with wasting of the 
respiratory muscles are life threatening and mostly 
become fatal before the third decade. On autopsy 
in late onset (juvenile and adult) cases glycogen 
storage is solely encountered in skeletal muscles. 
However, in some rare cases storage of glycogen 
has been described in vascular smooth muscle cells, 
leading to an aneurysm of the basilar or other in- 
tracranial a r t e r i e ~ . ~ ~ ’ ~ ’  
In practice, the clinical appearance of Pompe’s 
disease is a spectrum with an early onset and rap- 
idly progressive phenotype with cardiac involve- 
ment at one end and a late onset slowly progressive 
P 
0 
phenotype at the other.7 The clinical histories of 
20 patients diagnosed by our colleague, Dr. M.C.B. 
Loonen (neurologist, University Hospital Rotter- 
dam), are depicted in Figure 1. 
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LYSOSOMAL a-GLUCOSIDASE (ACID MALTASE) 
Lysosomal or acid a-glucosidase is the best name 
for this enzyme since the substrate specificity is not 
limited to maltose, and the catalytic activity not to 
hydrolysis of the 1,4-glycosidic bond. The natural 
substrate is glycogen. When engulfed by the lyso- 
soma1 system,6 glycogen is degraded to glucose 
whereby both the a-1,4 and a-1,6 linkages are 
cleaved. Also, activity for a-1,2 and a-1,3 diglyco- 
sidic bonds has been reported,26 which implies that 
carbohydrate structures other than glycogen may 
serve as natural substrate. 
The enzyme consists of 952 amino acids as de- 
duced from the cDNA sequence and shows struc- 
tural similarity with the intestinal enzymes su- 
crase and i~omaltase.’~ It is assumed that the three 
enzymes have arisen from a common ancestral 
gene. 15,20 The newly synthesized lysosomal a-glu- 
cosidase precursor has a signal peptide at the 
N-terminal end for guiding the nascent protein to 
the lumen of the endoplasmic r e t i c ~ l u m ’ ~  where 
N-linked glycosylation occurs at all the seven avail- 
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FIGURE 1. The clinical spectrum of Pompe’s disease: onset 
and course of the disease in 20 random cases. This figure 
was taken with permission from the academic thesis of Dr. 
M.C.B. Loonen (Erasmus University Rotterdam, 1979), and 
was made by analogy to the figure published by Engel AG, et 
al.: Neurology 1973;23:95-106. 
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able positions. Phosphorylation (mannose 6-phos- 
phate) occurs at two sites minimall~.’~ The relative 
molecular mass of this precursor is 110 kd.31*36 
Posttranslational processing during transport 
through the Golgi complex and trans-Golgi net- 
work, and in the lysosomes, leads to a stepwise 
mass reduction from 110 kd via 95 kd to 76 kd and 
finally 70 kd.9,31,36350 The  posttranslational modi- 
fication is complex and involves the proteolytic re- 
moval of both N- and C-terminal peptides in fixed 
order, and further, a partial alteration of the initial 
carbohydrate structures. T h e  conformational 
changes are essential for the development of cata- 
lytic activity. 18950 Figure 2 shows schematically the 
location of the seven glycosylation sites (Gl-G7) 
and the places of proteolytic cleavage. Also sum- 
marized in this figure are the amino acid substitu- 
tions that have been found in GSD I1 patients (dis- 
cussed separately). 
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NATURE OF THE LYSOSOMAL a-GLUCOSIDASE 
DEFICIENCY IN GSD II 
Activity. The discovery of acid maltase deficiency 
in a severe case of infantile Pompe’s disease has 
been the first important step in elucidating the mo- 
lecular basis of GSD II.14 The “same” enzyme de- 
ficiency was later also discovered in late onset vari- 
ants of the disease.53 The cause of this clinical 
heterogeneity remained obscure. The hypothesis 
of a coexistent deficiency of acid and neutral malt- 
ase activities in the severe form of GSD I1 as com- 
pared to a single acid a-glucosidase deficiency in 
the milder clinical forms was raised but could not 
be ~ u b s t a n t i a t e d . ~ ~  An alternative presumption 
that patients with a milder form of the disease 
would have a higher residual a-glucosidase activity 
was made,17,29,35,38,41,43 but left unexplained the 
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mild clinical phenotype of some adult atients with 
T o  reevaluate the latter presumption we have 
recently compared the level of residual a-glucosi- 
dase activity in cultured fibroblasts from patients 
with different clinical phenotypes. These cells are 
for several reasons more suitable for this type of 
study than muscle biopsy specimens or leukocytes: 
(i) fibroblast cell lines can be established and col- 
lected over the years and can be stored frozen in 
liquid nitrogen without loss of viability and enzyme 
activity, ensuring a large sample size; (ii) the cul- 
ture conditions are well controlled and the condi- 
tion of the cells can be monitored by visual inspec- 
tion and by recording the growth rate; (iii) the 
lysosomal glycogen accumulation in cultured fibro- 
blasts is moderate compared to muscle fibers35 and 
does not induce cellular damage with concurrent 
effects on lysosomal enzyme a c t i ~ i t i e s , ~ ’ ~ ~  more- 
over, the pathological changes in muscle tissue 
vary 10cally;~ and (iv) leukocyte preparations, 
which are the preferred material for the routine 
assay of many lysosomal enzymes, are not ideal for 
a-glucosidase assay, probably because of high and 
variable levels of neutral maltase activities. The  in- 
fluence of neutral maltase activities in fibroblasts is 
negligible, provided that the assay is performed at 
low pH. 
The data obtained with fibroblasts were col- 
lected in our diagnostic department over a 15-year 
period, and are summarized in Figure 3. The ac- 
tivity of each fibroblast cell line is depicted sepa- 
rately. The control series includes 84 cell lines 
from healthy individuals and ranges from 42 to 
160 nmol/h per milligram protein with an average 
activity of 97.5. Twenty of the 24 cell lines from 
patients with adult GSD I1 have activities ranging 
an exceptionally low residual activity. L 3 8  
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RESIDUAL a-GLUCOSIDASE ACTIVITY 
IN THE CLINICAL PHENOTYPES 
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FIGURE 3. Correlation between clinical phenotype and re- 
sidual a-glucosidase activity. The lysosomal a-glucosidase 
activity was measured in homogenates of cultured fibro- 
blasts from control individuals and patients with different 
clinical forms of GSD It. 4-Methylumbelliferyl-a-D-gluco- 
pyranoside was used as substrate at pH 4.0. The fibroblasts 
were cultured in Ham's F10 medium supplemented with 10% 
fetal calf serum and antibiotics, and harvested 4 days after 
having reached confluence. 
from 7 to 22 nmol/h per milligram (i.e., 7-23% of 
the average control activity), and four cell lines 
have significantly lower activities. Four cell lines 
were available from patients with juvenile GSD 11, 
all with a low but significant activity (2-6%). Pa- 
tients with severe infantile GSD I1 form the most 
homogeneous population in that none of the cell 
Iines exhibits more than 1% residual activity. 
Thus, Figure 3 shows a logical correlation be- 
tween the level of residual activity and the course 
of the disease. A similar correlation has been ob- 
served in a small series of muscle cell cultures.43 
This correlation can be taken as a starting point for 
understanding the cause of clinical diversity. Ef- 
fort can then be devoted to finding an explanation 
for the relatively mild clinical phenotype of some 
adult patients with an exceptionally low a-glucosi- 
dase activity. We have done so in one particular 
case of adult GSD I1 with 4% residual activity and 
noticed that a-glucosidase was normally synthe- 
sized, but disappeared during the subsequent for- 
mation of mature enzyme. Immunocytochemistry 
at the ultrastructural level suggested that the defi- 
ciency of lysosomal a-glucosidase activity was com- 
pensated in part by expansion and activation of the 
lysosomal system: a phenomenon seen in the af- 
fected but not in the unaffected muscle fibers.49 
Mutations. Since the stepwise cloning and charac- 
terization of the a-glucosidase gene, tools have be- 
come available to analyze GSD I1 at the DNA 
level. 15,16,23-25 Mutation analysis performed by 
several groups has resulted in the identification of 
a variety of molecular lesions. All mutations known 
to us at present are listed in Table 1, and the re- 
sulting amino acid substitutions are indicated by 
position in Figure 1. References to the publications 
in which these mutations were reported are given 
in the footnote of Table 1. Also included are mu- 
tations discovered in our laboratory that remained 
as yet unpublished. The genetic heterogeneity in 
GSD I1 is immediately evident. The mutations are 
spread over most of the exons and are of different 
nature. Single base-pair deletions, (double) inser- 
tions, and larger deletions occur besides missense 
and nonsense mutations. Also, splice defects with 
loss of coding sequences have been reported. Fre- 
quent mutations are the exon 18 deletion, which 
occurs in the Dutch patient population with an al- 
lele frequency of 0.13 among infants and adults, 
and the exon 2 deletion in adults (allele frequency 
0.35). Also AT525 and Pro545Leu seem to be 
more common mutations (see Table 1 for refer- 
ences). 
Some mutations are predictably deleterious by 
creating a stop codon at the (very) 5' end of the 
coding sequence (e.g., AT525 and Arg40Stop) or 
by leading to substantial loss of coding sequence 
(e.g., the deletions of exon 18, exon 2, and nt 
1456-1468). Other mutations are obviously harm- 
less because they do not result in an amino acid 
substitution or are also found in healthy individu- 
als (polymorphism). Caution has to be taken with 
predicting the effect of most other mutations. Ev- 
olutionary conservative amino acid substitutions 
such as Asp645Glu can be deleterious. Very drastic 
alterations such as Glu-Lys remain without effect 
when occurring at position 689, but are deleterious 
at position 52 1, adjacent to the catalytic carboxyl- 
ate at A ~ p 5 1 8 . ' ~  When doubt remains about the 
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Table 1. Deleterious and nondeleterious mutations in the lysosomal a-glucosidase gene. 
Exon Mutation aa Change Ref. 
A. Deleterious 
lntron 1 
2 
5 
8 
9 
10 
lntron 10 
11 
14 
15 
16 
18 
19 
5.  Nondeleterious 
2 
3 
5 
8 
9 
11 
12 
14 
15 
16 
17 
18 
19 
20 
T( - 13)G [Aexon 21 
C118T 
AT525 
T953C 
C1204T 
G 1432A 
A1 3 n t l 4 5 h  
G(+l )C [Aexon l o ]  
T1556C 
G1561A 
C1634T 
G1927A 
C1935A 
C1941G 
C2173T 
C2303G 
Aexon 18 
C2560T 
insC2741linsG2743 
G( - 82)C 
C( - 79)G 
G271A 
C324T 
G596A 
C642T 
A668G 
A921T 
A1 203G 
C1374T 
A1 581 G 
G1726A 
C1727G 
G1917A 
G2065A 
A21 33G 
G2238C 
A2338G 
G2446A 
A2553G 
C2780T 
C2808T 
G2862A 
AG2998lAG2999 
C3002T 
C3082T 
G3086C 
T3277C 
Al82aa 1+ 
Arg40Stop 
Th r l7hSh i f t  
Met318Thr 
Trp402Arg 
Gly478Arg 
Thr48hShift 
A38aa 48o-t 
Met519Thr 
Glu521 Lys 
Pro545Leu 
Gly643Arg 
Asp645Glu 
Cys647Trp 
Arg725Trp 
Pro768Arg 
A55aa 8 2 t h  
Arg854Stop 
Pro91hShift 
Noncoding 
Noncoding 
Asp91Asn 
Argl99His 
Ser214 
His223Arg 
Ala307 
Gln401 
Tyr458 
Arg527 
Gly576Ser 
Gly576Ala 
Val639 
Glu689Lys 
Thr711 
Trp746Cys 
lle780Val 
Va181611e 
Gly815 
Thr92711e 
Asp936 
Noncoding 
Noncoding 
Noncoding 
Noncoding 
Noncoding 
Noncoding 
CyslO8 
a.b 
UR 
C 
d 
e.f 
UR 
9 
b 
UR 
h 
C 
I 
1.k.l 
9 
UR 
m.g.n 
UR 
I 
f 
f 
0 
e f  
1.e.f 
1 . f  
UR 
h 
1.C.f 
I.] 
h.i.1.e.f 
UR 
UR 
f 
g 
I 
9 
f 
1.k 
1.e.f 
1.k 
UR 
J.k 
e 
f 
e.1 
e,f 
aBoerkoel N, et a/.: The lnternational Symposium on Glycolytic and Mitochondria/ Defects in Muscle and Nerve, Osaka, Japan, July 7-8, 1994; bHuie 
ML. et a/.: Hum Mol Genet 1994;3:2231-2236, 'Hermans MMP, eta].: Hurn Mol Genet 1994;3:2213-2218; dZhong N, etal.: Am J Hum Genet 
1991;49.635445; eHoefsloot LH, etal.: Biochem J 1990;272:493497; 'Martiniuk F, etal. :  DNA Cell Biol 1990;9:85-94; Wuie ML, eta/.:  Hum Mol 
Genet 1994;3:1081-1087; 'Hermans, MMP et a/.: Biochem Biophys Res Comm 1991;179:919-926; 'Hermans MMP, et a/.: Hurn Mutat 1993;2:268-273; 
'Hermans MMP, et a/.: Biochem J 1993;289:687-693; kHermans MMP, et a/.: Genomics 1993;16:3OMO1; 'Shie JJ, et a/: J lnher Metabol Dis 
1994;17:145-148; "Boerkoel N,  etal.: Am J Hum Genet 1992;51:1367. "Van der Kraan M, etal.: Biochem Biophys Res Comm 1994;203:1535-1541; 
OMarttniuk F, et a/.: Am J Hum Genet 1990;47:440-445; UR: authors' unpublished result 
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significance of a mutation, it is necessary to per- 
form a detailed analysis by site-directed mutagen- 
esis of the “wild-type’’ cDNA followed by expres- 
sion in eukaryotic cells. 
T o  correlate genotype and phenotype it is es- 
sential to know the effect of a given mutation ex- 
actly. The frequent occurrence of compound het- 
erozygotes is a complicating factor because the two 
mutant allele products have a combined effect. T o  
investigate the genotype-phenotype correlation in 
GSD I1 we have expressed the mutant allele prod- 
ucts transiently in COS cells. The residual activity 
in the COS cell expression system appeared to cor- 
relate percentagewise with the residual activity in 
the patients’ fibroblasts. lo,’ Moreover, similar de- 
fects in synthesis and posttranslational modifica- 
tion were observed in COS cells as in fibroblasts. 
Thus, mutation analysis via the COS cell system 
demonstrates the causal relation between muta- 
tion, defective enzyme biosynthesis, and loss of en- 
zymatic function. However, this sophisticated assay 
is not per se more informative about the cause of 
clinical diversity than the level of a-glucosidase ac- 
tivity realized (in fibroblasts) by the two mutant 
allele products in natural coexistence. Mutation 
analysis has the advantage that it provides the 
means to diagnose with certainty carriers in fami- 
lies at risk, which may be problematic by enzyme 
assay. Furthermore, insight in the genotype- 
phenotype correlation and better understanding 
of enzyme structure and function, obtained by mu- 
tation analysis, will help to design a strategy for 
therapy. 
PRENATAL DIAGNOSIS OF GSD II 
Prenatal diagnosis for the infantile type of GSD I1 
is reliably possible by chorionic villus sampling 
(CVS) or amniocentesis. We have performed pre- 
natal analysis in 114 pregnancies at risk for GSD I1 
and diagnosed 23 affected fetuses. The first 5 cases 
in this series, concerning the assay of a-glucosidase 
in cultured amniotic fluid cells, were reported 
nearly 20 years ago.30 The diagnostic test is com- 
plicated by the generally low activity of a-glucosi- 
dase in first-passage amniotic fluid cells (10-65 
nmol/h per milligram protein) compared to 42- 
160 nmol/h per milligram in cultured skin fibro- 
blasts. Activities as low as 3-4 nmoYh per milligram 
have been measured in a few pregnancies with an 
unaffected heterozygous fetus. However, with op- 
timal accuracy and sufficient experience, these low 
carrier levels can be distinguished reliably from the 
virtually complete deficiency of a-glucosidase in 
amniocytes from affected fetuses (i.e., < 1 nmoVh 
per milligram). 
T h e  introduction of CVS has strongly im- 
proved the prenatal diagnosis of GSD 11. The most 
important advantage of CVS obviously is that it is 
done at a much earlier gestational age (10-12 
weeks) than amniocentesis (15-16 weeks). More- 
over, the enzyme analysis can be carried out di- 
rectly on the chorionic biopsy making the diagnosis 
available within a day. The use of chorionic villi 
(CV) has also facilitated the diagnosis of GSD 11, 
because the activity of a-glucosidase in normal CV 
is much higher than in amniotic fluid cells, which 
results in a better separation of values indicating a 
carrier or an affected fetus, respectively. 
A definitive and correct diagnosis could be 
made by direct analysis of the CV in 41 of the 42 
pregnancies (Table 2). In 10 cases an almost com- 
plete deficiency of a-glucosidase left no doubt 
about the diagnosis of an affected fetus. In che 
remaining cases the activity was normal (n = 20), 
moderately reduced as expected for heterozygotes 
(n  = 111, or strongly reduced in 1 case (n = 1). In 
this exceptional case amniocentesis also indicated 
heterozygosity . 
Previous reports on small series of first-tri- 
mester diagnoses for GSD I1 have emphasized the 
risk of maternal tissue contamination of CV sam- 
ples? or have anticipated the possible presence of 
neutral a-glucosidase activity in CV and have used 
an immunoprecipitation method’ or maltose as 
substrate to prevent such interfering acti~ity.~‘ We 
have used a simple and rapid assay with artificial 
4-methylumbelliferyl a-D-glucopyranoside sub- 
strate at pH 4.0. The absence of activity in the CV 
of 10 affected pregnancies indicates that neither 
interfering enzyme activity nor the presence 
Table 2. Prenatal diagnosis in 42 pregnancies at risk for 
glycogenosis type I1 by chorionic villus sampling. 
~~ 
a-Glucosidase 
Chorionic villi activity* Diagnosis+ 
Pregnancies at risk 
n = 10 0 7-2 4 ( + ) homozygous 
n = l  13 ( -  ) heterozygous 
n = 11 3%77 ( - )  heterozygous 
( - )  heterozygous 
n = 20 90-258 or normal 
Controls 
n = 45 90-260 
‘Nanomoles per hour per milligram protein. 
f ( + )  = affected; all pregnancies were terminated and the diagnoses 
were confirmed by enzyme assay in cultured CV cells or fetal skin 
fibroblasts or both. (-) = Unaffected, the outcome of all pregnancies 
was an unaffected child. 
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of maternal tissue or enzyme has played a role in 
these cases. 
THERAPY 
The most exciting progress in the development of 
therapy for lysosomal storage diseases is the effec- 
tiveness of enzyme therapy in type 1 Gaucher's dis- 
ease.1933352 The rationale of the approach is that 
(macro)molecular compounds are able to enter 
cells by endocytosis and reach the lysosomal sys- 
Cell surface receptors can function as effi- 
cient mediators in this process.42 The first attempt 
at enzyme therapy for lysosomal diseases dates 
from 1965 when a patient suffering from infantile 
GSD IT received intravenous injections of a-gluco- 
sidase from Aspergllus niger.2 A 5-month-old infant 
was treated for 116 days with a similar enzyme 
prepara t i~n . '~  An increase of enzyme activity in 
the liver was recorded and a clearance of lysosomal 
glycogen was noted. However, the positive effects 
could not be maintained. T h e  treatment was 
stopped after 4 months because of a developing 
immune nephritis. The patient died of cardiore- 
spiratory insufficiency. At postmortem examina- 
tion the liver and spleen pathology was typical for 
advanced GSD 11. Also, other attempts at therapy 
with a-glucosidase from human placenta were un- 
successful. Without present-day knowledge, these 
early trials were bound to fail, because of insuffi- 
cient quality and quantity of the administered en- 
zyme. Moreover, in these trials it was not at- 
tempted to facilitate a-glucosidase uptake via cell 
surface receptors. The protocol for treatment of 
Gaucher's disease with enzyme therapy prescribes 
the use of placental glucocerebrosidase with mod- 
ified carbohydrate side chains so that the enzyme 
binds to mannose receptors on the cell surface of 
affected macrophages in liver (Kupffer cells), 
spleen, and bone marrow.4o Enzyme therapy is at 
present applied almost as a routine for the treat- 
ment of type 1 Gaucher's disease and appears to be 
effective although questions remain about the ex- 
act mechanism of action. 
Following the same basic principles we started 
to develop models for (re)testing the potential ef- 
fect of a-glucosidase administration to patients 
with GSD 11. The most essential information ob- 
tained so far is that enzyme administered to cul- 
tured fibroblasts and muscle cells is taken up in an 
efficient manner when containing mannose 6- 
phosphate groups, enabling the enzyme to bind to 
the mannose 6-phosphate r e ~ e p t o r . ~ ~ * ~ ~ , ~ ~ ~ ~ ~ , ~ ~  Ev- 
idence for lysosomal targeting and function was 
obtained most notably by the resulting breakdown 
of stored glycogen. The relatively long half-life of 
the ingested enzyme (approximately 6-9 days) is 
favorable for successful application. In a more re- 
alistic model system, preparations of human pla- 
cental and bovine testis a-glucosidase were admin- 
istered intravenously to healthy mice in a dose of 
180 pg per animal. The enzyme was recovered in 
various organs up to 9 days after injection. Most of 
it appeared to be taken up  by liver and spleen, 
virtually independent of the mannose 6-phosphate 
content. The enzyme was not found in brain indi- 
cating that the blood-brain barrier is not passed. 
Most importantly, however, uptake was obtained 
also in heart and skeletal muscle, the target organs 
in GSD 11. The increase of a-glucosidase activity 
obtained with bovine testis a-glucosidase contain- 
ing mannose 6-phosphate residues was higher 
than with placental enzyme lacking this recogni- 
tion signal.46 In theory, the 40% increase obtained 
should be sufficient to supplement the enzyme de- 
ficiency of patients, under the assumption that cel- 
lular pathology does not ensue at activity levels 
above 30% of the average control level (according 
to the data in Fig. 2). 
Although these results are promising, the ulti- 
mate effect of enzyme therapy in GSD I1 can only 
be tested in clinical trails in humans, preferably 
preceded by tests in animal models. With respect to 
the latter, the development of a mouse model of 
GSD I1 via mutagenesis of the murine a-glucosi- 
dase gene in embryonic stem cells is in progress. 
Animal models of lysosomal storage diseases have 
already proven their value. For instance, mice with 
a natural P-glucuronidase deficiency (mucopoly- 
saccharidosis type VIIISly syndrome in humans) 
have been used for investigating the effect of 
bone marrow transplantation, enzyme infusion, 
and implantation of a neo-organ with glucuro- 
nidase-producing  fibroblast^.^^,^^,^^ A prerequi- 
site to enzyme therapy in lysosomal storage dis- 
eases including GSD I1 is the realization of large 
scale production of (recombinant) enzyme. Pro- 
duction in genetically modified CHO cells is an 
option already applied for the production of glu- 
cocerebrosidase. An alternative approach we are 
exploring is production of human recombinant 
a-glucosidase in the milk of transgenic mammals. 
There are still obstacles toward therapy for GSD 
11, but the goal is challenging. 
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